Seminars in Colon & Rectal Surgery
Volume 18, Issue 4 , Pages 258-263 , December 2007

What Does It All Mean?

  • Richard L. Whelan, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Richard L. Whelan, MD, Columbia-Presbyterian Medical Center, Surgical Specialties, 161 Fort Washington Avenue, Suite 820, New York, NY.

References 

  1. Schwenk W, Haase O, Neudecker J, et al. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev. 2005;(3):CD003145
  2. The Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–2059
  3. Transatlantic Laparoscopically Assisted vs Open Colectomy Trials Study Group. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg. 2007;142:298–303
  4. Lacy AM, García-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–2229
  5. Sylla P, Nihalani A, Whelan RL. Microarray analysis of the differential effects of open and laparoscopic surgery on murine splenic T-cells. Surgery. 2006;139:92–103
  6. Trokel MJ, Bessler M, Treat MR, et al. Preservation of immune response after laparoscopy. Surg Endosc. 1994;8(12):1385–1388
  7. Allendorf JD, Bessler M, Whelan RL, et al. Better preservation of immune function after laparoscopic-assisted vs open bowel resection in a murine model. Dis Colon Rectum. 1996;39(suppl 10):S67–S72
  8. Kloosterman T, von Blomberg ME, Borgstein P, et al. Unimpaired immune functions after laparoscopic cholecystectomy. Surgery. 1994;115:424–428
  9. Whelan RL, Franklin M, Holubar SD, et al. Postoperative cell mediated immune response is better preserved after laparoscopic versus open colorectal resection in humans. Surg Endosc. 2003;17(6):972–978
  10. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;25:362–367
  11. Pietsch JB, Meakins JL, MacLean LD. The delayed hypersensitivity response: application in clinical surgery. Surgery. 1977;82:349–355
  12. Kirman I, Jain S, Cekic V, et al. Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early post-operative period in patients with colorectal cancer. Surg Endosc. 2006;20:482–486
  13. Lee SW, Gleason NR, Southall JC, et al. A serum-soluble factor(s) stimulates tumor growth following laparotomy in a murine model. Surg Endosc. 2000;14:490–494
  14. Lee SW, Gleason NR, Stapleton GS, et al. Increased platelet-derived growth factor (PDGF) release after laparotomy stimulates tumor growth in mice. Surg Endosc. 2001;15:981–985
  15. Kirman I, Cekic V, Poltaratskaia N, et al. Plasma from patients undergoing major open surgery stimulates in vitro tumor growth: lower insulin-like growth factor binding protein 3 levels may, in part, account for this change. Surgery. 2002;132:186–192
  16. Kirman I, Cekic V, Poltaratskaia N, et al. Open surgery induces a dramatic decrease in circulating intact IGF-BP3 in patients with colorectal cancer not seen with laparoscopic surgery. Surg Endosc. 2005;19:55–59
  17. Kirman I, Poltoratskaia N, Sylla P, et al. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery. 2004;136:205–209
  18. Belizon A, Balik E, Kirman I, et al. Insulin-like growth factor binding protein-3 inhibits colitis-induced carcinogenesis. Dis Colon Rectum. 2007;50:1377–1383
  19. Belizon A, Balik E, Kirman I, et al. Major abdominal surgery increases plasma levels of vascular endothelial growth factor; open more so than minimally invasive methods. Ann Surg. 2006;244(5):792–798
  20. Belizon A, Horst P, Balik E, et al. Persistent elevation of plasma VEGF levels during the first month following minimally invasive colorectal resection. Surg Endosc. 2007;(in press)
  21. Kumara S, Hoffman A, Nasar A, et al. Colorectal resection, open more so than minimally invasive in patients with benign indications is associated with proangiogenic changes in the plasma levels of angiopoietin 1 and 2. Surg Endosc. 2007;21:S352–S482
  22. Kirman I, Belizon A, Balik E, et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. Eur J Surg Oncol. 2007;May 16; [Epub ahead of print] PMID: 17512160
  23. Carter JJ, Feingold DL, Oh A, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov. 2006;13(1):41–44
  24. Hill AD, Redmond HP, Naama HA, et al. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery. 1996;119:178–185
  25. Sabel MS, Hill H, Jong YS, et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery. 2001;130:470–478
  26. Kirman I, Poltoratskaia N, Herlyn D, et al. Addition of interleukin-12 to GA733 tumor protein vaccine leads to development of tumor protective immunity despite surgical stress. Surg Endosc. 2003;17(7):1135–1139
  27. Kirman I, Asi S, Carter J, et al. Combined whole tumor cell and monophosohoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc. 2002;16(4):654–658
  28. Wildbrett P, Oh A, Carter JJ, et al. Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of this effect with perioperative immunomodulation. Surg Endosc. 2002;16(8):1162–1170

PII: S1043-1489(07)00055-3

doi: 10.1053/j.scrs.2007.10.010

Seminars in Colon & Rectal Surgery
Volume 18, Issue 4 , Pages 258-263 , December 2007

Article Tools